Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastomaAllison R. Hanaford, Eric H. Raabe, Jesse Alt et al.|Translational Oncology|2019Cited by 74
Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-NorleucineSabrina Wang, Jeffrey Rubens, Brad Poore et al.|Clinical Cancer Research|2019Cited by 34
The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicityJeffrey Rubens, Eric H. Raabe, Sabrina Wang et al.|Neuro-Oncology|2017Cited by 23
Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumorsAshlyn Parkhurst, Jeffrey Rubens, Tyler Findlay et al.|Cell Death and Disease|2022Cited by 8
ATRT-17. TARGETING GLUTAMINE METABOLISM LOWERS METHYLATION POTENCIALS IN AT/RT AND SYNERGIZE WITH TAZEMETOSTATSatoshi Nakata, Jeffrey Rubens, Sabrina Wang et al.|Neuro-Oncology|2020Cited by 1